Newsletter | November 20, 2026

11.20.26 -- The Hidden Risks Behind Green CDMO Metrics

SPONSOR

Key Considerations When Choosing A Device For Dry Powder Nasal Delivery

Dry powder nasal delivery is attracting growing interest as developers seek alternatives to traditional liquid nasal sprays. From improved stability and higher drug loading to enhanced bioavailability, the approach offers several compelling advantages. However, selecting the right device is critical to achieving successful drug delivery and clinical outcomes. This article explores the key factors that influence device selection, highlighting why early alignment between formulation and device development can help accelerate programmes and maximise product performance. Read more.

INDUSTRY INSIGHTS

Navigating The Complex Route To Regulatory Compliance

Could decisions made today impact your regulatory timeline years from now? Explore the value of early planning and regional expertise.

Ask Us Anything: Eric Fang On New Challenges In Pharma Development

Eric Fang discusses a two-part investment strategy: advanced technology that accelerates R&D insights and empowered scientists who solve the complex challenges technology alone cannot.

Considerations When Outsourcing Your Packaging Operations

View the key to maintaining and enhancing existing and new partnerships as well as how outsourcing one crucial aspect of bringing products to market can benefit overall supply chain optimization.

FEATURED EDITORIAL

The Hidden Risks Behind Green CDMO Metrics

A green CDMO quality dashboard can mask repeated deadline extensions, shallow “human error” investigations, and facility-wide excursions unless sponsors look past headline percentages to examine how the underlying metrics are built.

Is It Time To Leave Your CDMO?

This segment of the Outsourced Pharma Live event, “Your CDMO Quality Oversight Is Not Working,” examines how sponsors can determine whether a troubled CDMO relationship can be repaired.

INDUSTRY INSIGHTS CONTINUED

Integrate Ops And Supply Chain To Ensure Consistent Drug Availability

To ensure consistent drug supply, pharmaceutical companies must integrate operations and supply chain management for proactive planning and global risk mitigation.

From Brick Dust To Breakthrough: The Power Of Enabled Formulation

Enabled formulation strategies transform poorly soluble, highly lipophilic molecules into viable oral products by improving exposure, reducing burden, and ensuring manufacturable pathways.

Accelerated Development Of OSD Formulation For IND Submission

This paper highlights how the roller compaction process not only enhances efficiency but also improves the scalability of solid oral dosage production, supporting rapid development for regulatory approval.

Navigating The Development Of Dry Powder For Inhalation

Navigate Dry Powder Inhaler Development With Confidence. Explore key considerations for TPP definition, API characterization, particle engineering, technology selection, and encapsulation.

The Proposal Bottleneck: Why Timelines Slip And How To Prevent It

Proposal delays often start with missing information. Learn what CDMOs need to build accurate timelines, improve planning, and minimize costly scope changes.

Practical Formulation Strategies For Poorly Soluble APIs

Poor aqueous solubility now defines most drug candidates in development, making early screening and solid-state assessment essential to achieving exposure and avoiding costly reformulation downstream.

SPONSOR

Webinar: Building for What Comes Next: Robust Process Development and Analytical Strategies in Early Pharmaceutical Development

Successful drug development starts with strong collaboration between process and analytical teams. Join Cambrex experts to explore proven strategies, real-world case studies and best practices for reducing development risks, improving process robustness and supporting scale-up. Discover how early integration and external expertise can accelerate development, strengthen decision-making and improve the path to commercialization. Click here to learn more.

SOLUTIONS

End-To-End CDMO Solutions For Oral Solid Dosage Manufacturing

Primary And Secondary Packaging Solutions

Accelerating Highly Potent Drug Development From Lab To Launch

Your Trusted CDMO Partner In Pharmaceutical Development & Manufacturing

Our Small Molecule Development And Manufacturing Experience

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: